Elligo Health Research, an integrated research organization (IRO), announced the launch of its IntElligo Research Stack clinical technology. This standards-based technology platform, which powers the System of Accelerated Research (SOAR™)model, will be launched this month as the eSource documentation tool at Elligo’s Research Ready network of study sites.
”IntElligo can be set up per the study protocol in hours and easily follows the workflow in any physician’s office,” said Jacylyn Bodmer, Elligo’s chief information officer. “We are improving data quality while relieving administrative burden at the research site and enabling more patient-centric interactions. IntElligo also facilitates remote monitoring, which results in faster source data verification and financial payments to our physicians.”
“IntElligo bridges health care and research, leveraging global industry standards from the start (CDISC PRM and CDASH), thus facilitating aggregation and tabulation into CDISC SDTM, the required format for regulatory eSubmissions to the FDA and Japan’s PMDA,” added Rebecca Kush, Ph.D., Elligo’s chief scientific officer.
In addition, the technology provides real-time management financial management, reports, analytics across research sites, and achieves true eSource. Furthermore, it creates the opportunity to transform research through the SOAR model - expanding patient access and driving efficiency by enabling direct data from source to submission.
“By uniting our Goes Direct approach with this technology and infrastructure to support physicians, we are creating the ultimate solution for clinical trial execution,” said John Potthoff, Ph.D., Elligo CEO. “The IntElligo platform will become a primary resource for our study sites, increasing the ability for physicians to provide research as a care option and enabling more patients to benefit.”
Learn more at www.elligodirect.com
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.